Sodium Oxybate Versus Midazolam for Comfort Sedation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-14

Study Completion Date

2023-10-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aims at deepen the proof level of sodium oxybate use for comfort sedation at the end of life in a palliative care unit by comparing it to midazolam in a prospective randomized study with blinded efficacy evaluation. The study will be carried out for a period of 24 months with a recruitment objective of 22 patients with refractory suffering and with a short-term prognosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sedation of Mechanically Ventilated Critically Ill Patients: Midazolam Versus Dexmedetomidine

NCT01256866

Mechanically Ventilated Patients Sedation Dexmedetomidine +1 more

UNKNOWN PHASE4

Administration of Intranasal Midazolam for Anxiety in Palliative Care

NCT06330584

Anxiety Acute Anxiety Palliative Care

RECRUITING PHASE2

Dexmedetomidine Versus Midazolam for Continuous Sedation in the Intensive Care Unit (ICU)

NCT00481312

Continuous Sedation in Initially Sedated Adults in ICU

COMPLETED PHASE3

Effectiveness and Safety Study of Etomidate Versus Midazolam to Help Place a Breathing Tube Outside of the Hospital.

NCT00248729

Respiratory Failure

COMPLETED PHASE2

Study in Healthy Volunteers to Assess the Pharmacokinetics of Midazolam Administered Alone and in Combination With Vandetanib

NCT01544140

Healthy Volunteers

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In certain cases, terminally-ill patients may show persistent symptoms despite numerous efforts to find a comfort treatment without causing impaired consciousness. In these cases and after a collegial discussion, sedation may be offered.

Midazolam is then the most typically used sedative agent. However, it has limitations: frequent awakenings, tolerance and major respiratory depression. Furthermore, the use of midazolam as a "gold standard" in palliative sedation at the end of life falls under expert consensus without a high level of evidence.

Sodium oxybate (GammaOH®), is an ancient molecule used in anesthesia and other medical fields. It appears to be an attractive alternative to midazolam. Study hypothesis is as follows: deep sedation induced by sodium oxybate (RASS: -4 or -5) is more constant and sustainable than by using midazolam which can cause fluctuating effects and requires frequent dosage adjustments. The single-blind clinical trial aims at comparing the possibility to obtain constant deep sedation using midazolam or sodium oxybate. Before the induction, the patient is not aware of the medication used. The medical team must be aware of it because the two administration procedures are too different.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Palliative Care

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Participants

Participants won't be aware of the sedative treatment administered.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sodium oxybate

Group Type EXPERIMENTAL

Sodium Oxybate injection

Intervention Type DRUG

* Induction dosage : 60 mg/kg by direct intravenous injection.
* Continuous dosage : 45 mg/kg/h by continuous intravenous injection.
* Additional dosage if the Richmond Agitation Sedation Scale (RASS) score exceeds -4 : 1000 mg sodium oxybate by direct intravenous injection bolus every hour at most until RASS score reaches -4.

Sedation maintained until patient death.

Midazolam

Group Type ACTIVE_COMPARATOR

Midazolam injection

Intervention Type DRUG

* Induction dosage : 1 mg every 3 min by direct intravenous injection until RASS score reaches -4 (with a maximum of 30 min).
* Continuous dosage : Half of titration dosage every hour by continuous intravenous injection.
* Additional dosage if the RASS score exceeds -4 : 1 mg every 3 min by direct intravenous injection (without exceeding 10 mg/h).

Sedation maintained until patient death.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sodium Oxybate injection

* Induction dosage : 60 mg/kg by direct intravenous injection.
* Continuous dosage : 45 mg/kg/h by continuous intravenous injection.
* Additional dosage if the Richmond Agitation Sedation Scale (RASS) score exceeds -4 : 1000 mg sodium oxybate by direct intravenous injection bolus every hour at most until RASS score reaches -4.

Sedation maintained until patient death.

Intervention Type DRUG

Midazolam injection

* Induction dosage : 1 mg every 3 min by direct intravenous injection until RASS score reaches -4 (with a maximum of 30 min).
* Continuous dosage : Half of titration dosage every hour by continuous intravenous injection.
* Additional dosage if the RASS score exceeds -4 : 1 mg every 3 min by direct intravenous injection (without exceeding 10 mg/h).

Sedation maintained until patient death.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Gamma-Hydroxybutyric acid 4-hydroxybutanoic acid

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patient hospitalized in a palliative care unit
* patient aged 18 or over
* patient with an estimated vital prognosis of a few hours to a few days\*
* patient with persistent suffering despite optimal palliative care\*
* patient gave informed consent in advance or if unable to do so, consent given by a family member or legal representative (patients under guardianship)
* patient covered by a social security scheme. \* Validated after collegial and multidisciplinary discussion including the opinion of a doctor outside the palliative care team.

Exclusion Criteria

* contraindication or known allergy to sodium oxybate or midazolam
* significant risk of seizure
* venous access not possible
* pregnancy or breastfeeding
* person in exclusion period from another research protocol at the time of consent signing
* any condition which in the investigator's opinion could increase and jeopardize persons safety in case of research participation

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No